Clovis To Pay $20M To End SEC Claims Over Cancer Drug
Biomedical firm Clovis Oncology Inc. and two of its executives will pay more than $20 million in penalties to resolve U.S. Securities and Exchange Commission claims that the company misled investors...To view the full article, register now.
Already a subscriber? Click here to view full article